Citigroup
ARTL icon

Citigroup’s Artelo Biosciences ARTL Stock Holding History

Citigroup’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-342
Closed -$23.3K – 5719
2026
Q1 		$23.3K Buy
+342
New +$14.6K ﹤0.01% 4780
2025
Q4 		– Sell
-18
Closed -$2.19K – 6055
2025
Q3 		$2.19K Buy
+18
New +$4.96K ﹤0.01% 5461
2025
Q2 		– Hold
0
– – – 5506
2024
Q3 		– Hold
0
– -$64 – 5671
2024
Q2 		– Hold
0
– – – 5468

Other funds holding ARTL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Citigroup's ARTL Position: Q2 2026 in Review

Citigroup sold out of Artelo Biosciences (ARTL) in Q2 2026, closing a stake of 342 shares — an estimated $23.3K sold.

Citigroup first reported a position in ARTL in Q3 2025 and held it in 2 quarters. The position peaked at $23.3K in Q1 2026. 7 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

  • Citigroup reported no remaining Artelo Biosciences position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 342 Artelo Biosciences shares in Q2 2026, an estimated $23.3K.
  • Citigroup first reported a position in Artelo Biosciences in Q3 2025 and held it in 2 quarters.
  • Citigroup's Artelo Biosciences position peaked at $23.3K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.